.Pharmacolibrary.Drugs.ATC.J.J04AK06

Information

Delamanid is a nitro-dihydro-imidazooxazole derivative indicated for the treatment of multidrug-resistant pulmonary tuberculosis (MDR-TB). It acts by inhibiting mycolic acid synthesis in Mycobacterium tuberculosis. Delamanid is approved in several countries for MDR-TB therapy, typically as part of a combination regimen.

Pharmacokinetics

Pharmacokinetic parameters reported in adult healthy volunteers after oral administration.

References

1. Tanneau, L, et al., & Svensson, EM (2022). Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline. Clinical pharmacokinetics 61(8) 1177–1185. DOI:10.1007/s40262-022-01133-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35668346

2. Ramirez, G, et al., & Boyd, BJ (2021). Sustained absorption of delamanid from lipid-based formulations as a path to reduced frequency of administration. Drug delivery and translational research 11(3) 1236–1244. DOI:10.1007/s13346-020-00851-z PUBMED:https://pubmed.ncbi.nlm.nih.gov/32935235

3. Zou, Y, et al., & Garcia-Prats, A (2025). Relative bioavailability of delamanid 50 mg tablets dispersed in water in healthy adult volunteers. British journal of clinical pharmacology 91(4) 957–967. DOI:10.1111/bcp.15672 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36692865

Revisions

• 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)